SK bioscience Completes L HOUSE Expansion to Boost Vaccine Production

• SK bioscience has expanded its L HOUSE facility in Andong by 4,200㎡ to support production of GBP410, a 21-valent pneumococcal conjugate vaccine candidate developed with Sanofi.

• The company aims to secure U.S. FDA cGMP certification following the facility’s local approval for use.

SK bioscience, a South Korea-based vaccine and biotech company, has completed a major expansion of its L HOUSE production facility in Andong to support global supply of its 21-valent pneumococcal conjugate vaccine (PCV) candidate, GBP410. The facility has now received official building use approval from the City of Andong.

The expansion adds two new floors and approximately 4,200㎡ of production space to the vaccine manufacturing department. It was jointly funded with global pharmaceutical company Sanofi, which is co-developing GBP410. The move is intended to prepare the site for commercial-scale production and to position it as a hub for global vaccine supply.

SK bioscience plans to obtain the U.S. FDA’s cGMP certification, a critical regulatory requirement for pharmaceutical production. The L HOUSE facility previously achieved EU-GMP certification from the European Medicines Agency in 2021, underscoring its global manufacturing standards.

GBP410 is currently in global Phase 3 trials involving over 7,700 participants across multiple countries. It is the first PCV candidate with more than 20 serotypes to reach this stage in infants and toddlers. According to the World Health Organization, Streptococcus pneumoniae causes around 300,000 deaths annually in children under five, highlighting the need for advanced pneumococcal vaccines.

“The expansion of L HOUSE marks a key milestone in establishing the facility as a global vaccine hub,” said Jaeyong Ahn, CEO of SK bioscience. “Through our successful partnership with Sanofi, we will continue to lead as Korea’s premier vaccine company and contribute to advancing global public health.”